Track market-moving stories before they get noisy

Greenland Capital Management LP cut its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 25.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 80,000 shares of the company's stock after selling 27,500 shares during the

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

Key Takeaways Teva's TEV '408 met the primary endpoint in a phase IIa study in adults with celiac disease.TEV '408 reduced gluten-induced intestinal damage, inflammation and gastrointestinal symptoms versus placebo.TEV '408's celiac and vitiligo programs support its potential as a pipeline-in-a-product opportunity. Teva Pharmaceutical Industries Limited (TEVA - Free Report) announced that the phase IIa study, which evaluated its investigational anti-interleukin-15 monoclonal antibody, TEV ‘408, in adult patients with celiac disease, has met its primary endpoint.

Data from the study showed that treatment with a single subcutaneous dose of TEV ‘408 led to a statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8.

TEV ‘408 showed a favorable effect on intestinal inflammation and lower gastrointestinal symptom scores versus placebo. Treatment with TEV ‘408 was also generally well-tolerated, with no safety signals reported to date.

The randomized, placebo-controlled phase IIa study enrolled 50 adult patients with celiac disease who were following a gluten-free diet. Teva said additional analyses from the study are currently underway and plans to present further data at a future medical conference.

Currently, there are no approved therapies for treating celiac disease.

TEVA’s Price PerformanceYear to date, shares of Teva have rallied 20.1% compared with the industry’s increase of 6.1%.

Image Source: Zacks Investment Research

More on TEVA’s Development Activities With TEV ‘408Besides celiac disease, TEV-'408 is also being developed for vitiligo.

In July 2026, Teva announced plans to advance its investigational anti-IL-15 antibody TEV-'408 into a phase IIb study for vitiligo in the fourth quarter of 2026 following encouraging phase Ib results.

Designed for once-every-12-week subcutaneous dosing, TEV-'408 targets the IL-15 pathway, a key driver of vitiligo biology, and could provide a convenient treatment option for patients with limited therapeutic alternatives.

Per management, the above-mentioned celiac disease results, together with its vitiligo program, further support TEV ‘408’s potential as a pipeline-in-a-product opportunity in multiple diseases.

Teva also has several key branded pipeline assets in neuroscience and immunology, which it believes represent a multi-billion-dollar commercial opportunity. These include olanzapine LAI, a long-acting subcutaneous injectable for schizophrenia, and ecopipam, which was acquired through Emalex Biosciences and is being developed for pediatric Tourette syndrome. Both candidates are under U.S. regulatory review, with Teva targeting potential launches of olanzapine LAI in the fourth quarter of 2026 and ecopipam in the first half of 2027, subject to approval.

Another key pipeline asset is duvakitug, a late-stage anti-TL1A therapy being developed for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease. Teva believes duvakitug also has pipeline-in-a-product potential.

TEVA's Zacks Rank & Stocks to ConsiderTeva currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) , Anika Therapeutics (ANIK - Free Report) and Precigen (PGEN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61 during the same time. RGEN’s shares have gained 5.6% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for Anika Therapeutics’ 2026 bottom line have moved from a loss of 12 cents per share to earnings of $1.05 per share, while estimates for 2027 have increased from 16 cents to 95 cents during the same time. ANIK’s shares have surged 124.3% year to date.

Anika Therapeutics’ earnings beat estimates in each of the trailing three quarters, with the average surprise being 950.00%.

Over the past 60 days, estimates for Precigen’s 2026 bottom line have moved from a loss of 2 cents per share to earnings of 25 cents, while estimates for 2027 have increased from 25 cents to 86 cents during the same time. PGEN’s shares have rallied 67.5% year to date.

Precigen’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 108.96%.

MarketBeat Week in Review – 02/03 - 02/07Teva Pharmaceutical Industries NYSE: TEVA reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company saying the treatment met its primary endpoint and showed statistically significant effects on key measures of intestinal damage.

The randomized study enrolled 50 adults with celiac disease, assigning participants one-to-one to TEV-408 or placebo. Patients received a single dose on day one, followed two weeks later by a six-week gluten challenge of 3 grams per day, an amount Teva described as roughly equivalent to a slice of standard bread.

Get TEVA alerts:

Teva Pharma: Why This Generic Drug Giant Is a Smart Buy NowAccording to Eric Hughes, Teva’s executive vice president of global R&D and chief medical officer, the study evaluated the ratio of villous height to crypt depth, a biopsy-based measure of intestinal injury in celiac disease. The placebo group saw its ratio decline by 0.88, compared with a 0.43 decline in the TEV-408 group, producing a treatment-placebo difference of 0.45.

Hughes said the 0.4 threshold is considered clinically meaningful and that the primary endpoint was statistically significant. The company also reported a statistically significant result on intraepithelial lymphocytes, immune cells associated with inflammation and intestinal damage in celiac disease. The placebo group experienced an increase of 27.6 cells per 100 enterocytes, while the TEV-408 group saw little change, resulting in a reported delta of 27.23.

Single-Dose Study and Safety Profile 2 Generic Drug Stocks Ready to Surge in 2025Teva said the study’s results followed only one dose of TEV-408, despite the antibody’s potential dosing schedule of once every three months. Hughes said Phase I data showed an approximately 38-day half-life and suppression of free IL-15 to essentially below detectable levels for 80 to 90 days at higher tested doses.

The company characterized the treatment as well tolerated to date, with no concerning safety signals identified across its development program. Teva said it has conducted a Phase I program involving 115 participants with follow-up extending to two years, in addition to an earlier Phase Ib celiac disease challenge study and clinical data in vitiligo.

In the prior celiac study, Teva observed changes in fatty acid-binding protein, a biomarker associated with gut inflammation. Hughes said those results suggested TEV-408 may have protected the gut from gluten exposure and potentially affected underlying “smoldering” disease activity.

TEV-408 has received Fast Track designation in celiac disease, Hughes said. Teva plans to present the new data to the U.S. Food and Drug Administration and other regulators to determine the next stage of development.

Next Steps in Celiac Disease Development Hughes said future Phase II work is expected to include dose-ranging of TEV-408 itself, longer treatment exposure and further evaluation of both biopsy findings and patient-reported symptoms. Teva used the Celiac Disease Symptom Diary in the Phase IIa study and reported a trend toward protection from symptoms including abdominal pain, diarrhea, nausea, bloating and fatigue.

The company did not provide timing for the next celiac Phase II study or a subsequent Phase III program, saying those plans will depend on discussions with regulators. Hughes said Teva is considering studies involving lower-level, simulated inadvertent gluten exposure for longer-duration trials, rather than the more intensive gluten challenge used in the proof-of-concept study.

On longer-term safety requirements, Hughes said programs generally require approximately 300 patients with six months of exposure and a total safety database of roughly 1,000 to 1,400 patients, while noting that final requirements could vary.

Teva said it also plans to develop TEV-408 in vitiligo through a seamless Phase II/III design expected to begin this year. The company may later consider additional IL-15-mediated conditions, including alopecia areata, eosinophilic esophagitis and potentially atopic dermatitis.

Broader Pipeline Strategy President and CEO Richard Francis said the TEV-408 results represent progress in Teva’s “Pivot to Growth” strategy, which aims to expand the company’s innovative medicines portfolio alongside its generics business. Francis said Teva sees an opportunity for five product submissions over five years and that its highlighted programs and indications have the potential to generate more than $10 billion in sales over time.

Francis said Teva does not currently plan to partner TEV-408, citing its commercial capabilities and its ability to fund development across multiple indications. He also highlighted upcoming milestones, including completion of the DARI asthma study, a futility analysis for emrusolmin, a potential fourth-quarter launch of long-acting olanzapine and a planned early-2027 ecopipam launch following priority review.

About Teva Pharmaceutical Industries (NYSE:TEVA)Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?Before you consider Teva Pharmaceutical Industries, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.

While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) on Wednesday reported encouraging topline outcomes from an active Phase 2a clinical trial evaluating TEV ‘408, an experimental anti-interleukin-15 monoclonal antibody, for celiac disease.

Coeliac disease is a chronic autoimmune condition where eating gluten damages the lining of the small intestine.

The trial successfully achieved its primary goal, revealing that the investigational treatment significantly prevented intestinal damage caused by gluten consumption when compared to a placebo at the eight-week mark.

Study Design And Clinical MethodologyResearchers enrolled 50 adult patients diagnosed with celiac disease who maintained a strict gluten-free diet and displayed minimal intestinal damage at the study’s onset.

Two weeks following a single administration of the TEV ‘408 antibody, the participants initiated a rigorous six-week daily gluten challenge.

Read Next

The clinical trial team evaluated patient-reported symptoms alongside comprehensive biopsy measurements to track intestinal inflammation and structural damage.

Key Efficacy And Inflammation MetricsAt the conclusion of the eight-week gluten challenge, TEV ‘408 demonstrated a clinically meaningful defense against gluten-induced damage.

The treatment yielded a least squares mean change in the trial’s primary endpoint, the villous height-to-crypt depth ratio, of -0.43. This significantly outperformed the placebo group’s -0.88 change.

Furthermore, the investigational antibody positively impacted intestinal inflammation.

Participants receiving TEV ‘408 experienced a minimal increase of 0.37 in intraepithelial lymphocyte density. In contrast, the placebo group saw a substantial surge of 27.60 in the same inflammatory marker.

Symptom Relief And Ongoing ResearchPatients treated with TEV ‘408 also recorded lower gastrointestinal symptom scores on the Celiac Disease Symptom Diary when compared to those taking the placebo.

Medical professionals noted that participants tolerated the treatment well, with no emerging safety concerns or signals identified throughout the process.

Teva is currently conducting additional analyses of the ongoing Phase 2a study.

TEVA Price Action: Teva Pharmaceutical Indus shares were up 3.04% at $37.29 at the time of publication on Wednesday. The stock is approaching its 52-week high of $38.36, according to Benzinga Pro data.

Read Next

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Israeli drugmaker Teva Pharmaceutical Industries (TEVA.TA), said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults ​with celiac disease, meeting the main goal of a ‌mid-stage trial.

U.S.-listed shares of the company were up over 4% in premarket trading.

Celiac disease is an autoimmune condition in which gluten triggers an ​immune response that damages the small intestine. It affects ​about 1% of the global population, including more than ⁠3 million people in the United States, according to ​Teva.

The antibody treatment, known as TEV-408, blocks IL-15, a protein involved ​in the immune reaction to gluten.

In the study, 50 patients following a gluten-free diet were randomly assigned to receive a subcutaneous injection of TEV-408 ​or a placebo. Two weeks after receiving a single ​dose, participants were instructed to consume gluten daily for six weeks.

A single injection ‌significantly ⁠reduced damage and inflammation in the small intestine compared with a placebo after eight weeks. Patients also reported fewer digestive symptoms, Teva said, adding that no new safety concerns were ​identified.

There are no ​approved treatments ⁠for the condition. Patients rely on a strict gluten-free diet, though accidental exposure can still cause ​symptoms and intestinal damage.

Teva plans further analysis ​and will ⁠present additional results at a future scientific meeting. TEV-408 is also being tested for vitiligo and is set to enter another ⁠mid-stage ​trial for the skin condition.

Royalty Pharma (RPRX.O) ​agreed in January to provide Teva with up to $500 million to accelerate the ​drug's development.

Key Takeaways Teva bids for BioXcel assets, including Igalmi, in a court-supervised auction process.BXCL501 is under FDA review for potential at-home treatment of acute agitation in adults.Teva would pay $57.5 million upfront, with up to $67.5 million in contingent payments. Teva Pharmaceutical Industries Limited (TEVA - Free Report) announced it has made a bid to acquire certain assets of BioXcel Therapeutics, including the Igalmi (dexmedetomidine) sublingual film.

Igalmi, the currently approved formulation of dexmedetomidine sublingual film, is indicated for the acute treatment of agitation associated with schizophrenia and bipolar I or II disorder in adults when administered under the supervision of a healthcare provider.

Teva has agreed to serve as the “stalking horse bidder” in a court-supervised auction process for the assets. The proposed transaction does not involve the complete acquisition of BioXcel as a whole. However, Teva would acquire the assets if it is selected as the successful bidder, subject to bankruptcy court approval, potential higher bids and customary closing conditions.

Year to date, shares of Teva have risen 16.7% compared with the industry’s rise of 6.4%.

Image Source: Zacks Investment Research

TEVA’s Potential Neuroscience OpportunityThe key asset is BXCL501, a novel, orally dissolving dexmedetomidine sublingual film that is currently under FDA review for potential at-home use in the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. A decision from the regulatory body is expected on Nov. 14, 2026.

If approved, the product could potentially become the first FDA-approved at-home treatment for this condition, providing an option for patients outside traditional healthcare or hospital settings.

The proposed transaction would give Teva worldwide rights to the related assets, including the investigational formulation under FDA review for potential outpatient use.

What's Driving TEVA’s Interest?Under the above agreement, Teva would pay $57.5 million upfront for the assets, with the potential for up to an additional $67.5 million in contingent payments. The additional payments include time-based payments tied to the timing of FDA approval, potential approval delays and specified sales milestones.

The proposed transaction fits Teva’s strategy of pursuing assets that offer a strategic fit, address patient needs and have the potential to generate long-term value. Management expects that, if successful, the deal would strengthen its neuroscience portfolio while maintaining a disciplined approach to capital allocation and risk.

The move underscores Teva’s ongoing focus on targeted business development as part of its Pivot to Growth strategy.

Teva recently expanded its neuroscience pipeline through the acquisition of Emalex Biosciences, adding ecopipam, an investigational therapy being developed for treating pediatric Tourette syndrome.

In August 2026, the FDA accepted the new drug application ("NDA") seeking approval for ecopipam for the treatment of pediatric patients with Tourette syndrome.

With the FDA granting priority review to the NDA, a decision from the regulatory body is expected in late first quarter of 2027. If approved, ecopipam could become the first new Tourette syndrome therapy in more than 10 years and the first novel mechanism of action in more than 50 years.

TEVA's Zacks Rank & Stocks to ConsiderTeva currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) and Anika Therapeutics (ANIK - Free Report) , both sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61 during the same time. RGEN’s shares have gained 7.6% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for Anika Therapeutics’ 2026 earnings per share have risen from 41 cents to $1.05, while estimates for 2027 have increased from 46 cents to 95 cents during the same time. ANIK’s shares have surged 119.6% year to date.

Anika Therapeutics’ earnings beat estimates in each of the trailing three quarters, with the average surprise being 950.00%.

BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Agreement is part of a court-supervised sale process with BioXcel Therapeutics, Inc. and remains subject to bankruptcy court approval, potential higher bids, and customary closing conditions. Transaction reflects Teva’s targeted business development approach focused on strategic fit, patient needs, and potential long-term value.  TEL AVIV, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) today announced it has made a bid to acquire an innovative neuroscience product from BioXcel Therapeutics, Inc. through a court-supervised sale process. The novel dexmedetomidine sublingual film is under U.S. Food and Drug Administration (FDA) review for potential at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. If approved, it could become the first FDA-approved at-home treatment for this condition. If the transaction is completed, the asset would expand Teva’s psychiatry portfolio and, pending FDA approval, could help address a meaningful unmet need for people living with complex mental health conditions. 

“Business development plays a critical role in accelerating our Pivot to Growth strategy,” said Evan Lippman, Executive Vice President, Business Development at Teva. “This opportunity strengthens our neuroscience portfolio and reflects our disciplined approach to pursuing innovative assets with a clear strategic fit, the potential to make a meaningful difference for patients and attractive long-term growth potential, while balancing risk and value creation."

For people living with schizophrenia or bipolar I or II disorder, agitation episodes can be unpredictable, disruptive, and distressing for patients, families, and caregivers. In some cases, these episodes may lead to escalation of care, including emergency department visits or hospitalization. Despite this burden, acute treatment options specifically designed for agitation remain limited, particularly options that may be used outside healthcare and hospital settings.

About the Proposed Transaction 
Teva has entered into an agreement with BioXcel Therapeutics, Inc., to serve as the “stalking horse bidder” in a court-supervised auction process, pursuant to Section 363 of Chapter 11 of the U.S. Bankruptcy Code, for the purchase of certain assets from BioXcel Therapeutics and its affiliates, including IGALMI®, its dexmedetomidine sublingual film. As the stalking horse bidder, Teva's proposal establishes the initial bid for the assets. The proposed transaction does not involve the acquisition of BioXcel Therapeutics as a whole. 

Teva would acquire the agreed-upon assets if Teva is selected as the successful bidder during the auction, required conditions are satisfied, and the transaction is approved by the Bankruptcy Court. If Teva is not the successful bidder, Teva would be entitled to a break-up fee and expense reimbursement, subject to the terms of the agreement. 

Under the terms of the Agreement, Teva would acquire worldwide rights to the assets including dexmedetomidine sublingual film for an upfront payment of $57.5 million and up to an additional $67.5 million in contingent payments. These include a range of time-based payments linked to the timing of the pending FDA approval, including potential delays in approval, as well as payments tied to the achievement of specified sales milestones. 

About dexmedetomidine sublingual film (BXCL501) 
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist. Dexmedetomidine sublingual film is a proprietary, investigational, orally dissolving film formulation currently under FDA review for at-home use in the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026. 

About IGALMI® 
IGALMI® (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a healthcare provider, which is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI have not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective in children. IGALMI® is a registered trademark of BioXcel Therapeutics, Inc. 

IGALMI IMPORTANT SAFETY INFORMATION
IGALMI can cause serious side effects, including:

Decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low blood volume, diabetes, chronic high blood pressure, and older patients. IGALMI is taken under the supervision of a healthcare provider who will monitor vital signs (like blood pressure and heart rate) and alertness after IGALMI is administered to help prevent falling or fainting. Patients should be adequately hydrated and sit or lie down after taking IGALMI and instructed to tell their healthcare provider if they feel dizzy, lightheaded, or faint.Heart rhythm changes (QT interval prolongation). IGALMI should not be given to patients with an abnormal heart rhythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death. Patients should be instructed to tell their healthcare provider immediately if they feel faint or have heart palpitations.Sleepiness/drowsiness. Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours after taking IGALMI.Withdrawal reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the first dose. Physical dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased response to IGALMI may occur if IGALMI is used longer than 24 hours.
  The most common side effects of IGALMI in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing.

These are not all the possible side effects of IGALMI. Patients should speak with their healthcare provider for medical advice about side effects.

Patients should tell their healthcare provider about their medical history, including if they suffer from any known heart problems, low potassium, low magnesium, low blood pressure, low heart rate, diabetes, high blood pressure, history of fainting, or liver impairment. They should also tell their healthcare provider if they are pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart rate, or take anesthetics, sedatives, hypnotics, and opioids.

Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088 or [email protected].

Please see full prescribing information at Igalmi.com.

About Teva Advisors 
Guggenheim Securities, LLC served as financial advisors and Ropes & Gray LLP served as legal advisors to Teva.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars, and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause Teva’s future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “developing,” “target,” “may,” “expand,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: our ability to successfully complete the acquisition of certain assets from BioXcel Therapeutics, Inc., which remains subject to bankruptcy court approval, potential higher bids and customary closing conditions; our ability to obtain regulatory approval for and successfully commercialize the novel dexmedetomidine sublingual film; our ability to successfully compete in the marketplace including our ability to develop and commercialize ecopipam and additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in this press release and in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. 

Teva Media Inquiries
[email protected]

Teva Investor Relations Inquiries
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/68cd1f4d-02f6-4b28-8723-30ad8605f8b5

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business... Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business...

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday’s premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

This news comes amidst a mixed market backdrop, with S&P 500 futures showing a slight loss of 0.03%.

Aurinia (AUPH) Settles Patent Litigation With TevaUnder the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the ‎U.S. of its generic voclosporin product.

The settlement further provides that Teva may launch its generic voclosporin product no earlier than Dec. 7, 2036, unless certain defined contingencies occur earlier.

In January 2021, Aurinia introduced Lupkynis (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis.

The company is also developing aritinercept, a dual inhibitor of B cell-activating factor and a proliferation-inducing ligand for autoimmune diseases.

Read Next

AUPH Technical Outlook: Trend, Momentum And Key LevelsThe stock has shown a solid performance over the past year, gaining approximately 34.64%.

Currently, it is trading above its 20-day simple moving average (SMA) of $15.31, which indicates a bullish short-term trend. The 50-day SMA is at $15.89, suggesting that while the stock is performing well, it still has some resistance to overcome in the medium term.

The moving average convergence divergence (MACD) is above its signal line, indicating that downside pressure is easing and momentum is improving. This suggests a potential for further upward movement if the current trend continues.

Key Resistance: $19.25 — This level is significant as it marks the 52-week high, which could act as a barrier to further price increases. Key Support: $15.31 — This level aligns with the 20-day SMA, providing a cushion for the stock in case of a pullback. How Aurinia (AUPH) Ranks On Value And MomentumBelow is the Benzinga Edge scorecard for Aurinia Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:

Value: 63.91 — Indicates a relatively favorable valuation compared to peers. Momentum: 71.77 — Suggests that the stock is currently outperforming the broader market. The Verdict: Aurinia Pharmaceuticals’s Benzinga Edge signal reveals a balanced profile with strong momentum and favorable value indicators. This positioning may attract investors looking for growth opportunities in the biopharmaceutical sector.

AUPH Stock Price Activity: Aurinia Pharmaceuticals shares were up 2.66% at $16.60 during premarket trading on Thursday, according to Benzinga Pro data.

Image via Shutterstock

Read Next

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.

Posted by Defense World Staff on Aug 8th, 2026

Assenagon Asset Management S.A. lifted its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 128.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 3,056,017 shares of the company’s stock after purchasing an additional 1,716,315 shares during the period. Assenagon Asset Management S.A. owned about 0.27% of Teva Pharmaceutical Industries worth $103,538,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Legal & General Group Plc boosted its holdings in Teva Pharmaceutical Industries by 6.8% in the fourth quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock worth $112,618,000 after acquiring an additional 228,189 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 8.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,082,578 shares of the company’s stock valued at $33,506,000 after acquiring an additional 80,106 shares in the last quarter. Norges Bank purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $1,098,060,000. TD Asset Management Inc raised its position in shares of Teva Pharmaceutical Industries by 47.1% in the 4th quarter. TD Asset Management Inc now owns 369,023 shares of the company’s stock valued at $11,517,000 after purchasing an additional 118,075 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Teva Pharmaceutical Industries in the 1st quarter worth approximately $9,126,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling In related news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the completion of the transaction, the executive vice president directly owned 172,184 shares in the company, valued at approximately $6,131,472.24. This represents a 47.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.54% of the company’s stock.

Analyst Ratings Changes A number of research analysts have issued reports on the stock. Weiss Ratings raised shares of Teva Pharmaceutical Industries from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, July 31st. Barclays upped their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. UBS Group raised their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, Truist Financial increased their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.00.

Get Our Latest Report on TEVA

Teva Pharmaceutical Industries Trading Up 1.4% Shares of TEVA stock opened at $35.30 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries Ltd. has a twelve month low of $16.08 and a twelve month high of $37.35. The company’s 50-day moving average price is $33.25 and its 200-day moving average price is $32.82. The stock has a market cap of $40.59 billion, a price-to-earnings ratio of 58.83, a PEG ratio of 3.72 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. As a group, equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.96 earnings per share for the current year.

Teva Pharmaceutical Industries Profile (Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

See Also Five stocks we like better than Teva Pharmaceutical Industries Datadog’s Drop Says More About Expectations Than Earnings D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus Solventum Nears Inflection Point As It Begins to Unlock Value Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report).

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEComparing Crawford & Company (NYSE:CRD.B) & Globe Life (NYSE:GL)

NEXT HEADLINE »Sachem Capital Corp. 7.125% Not (OTCMKTS:SCCB) & Blackstone Mortgage Trust (NYSE:BXMT) Head to Head Contrast

Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors?

Teva Pharmaceutical Industries Limited is executing a successful turnaround, driven by its "Pivot to Growth" strategy and strong innovative medicines performance. Management raised 2026 guidance for Austedo, Ajovy, and Uzedy, targeting $3.7B specialty revenue (17% y/y growth) and a robust pipeline through 2030. Generics and biosimilars remain stable, funding R&D for innovation, while margin improvements and debt reduction enhance the risk/reward profile.

Teva Pharmaceutical (TEVA -1.13%) stock closed out the last week of trading with significant gains, rising roughly 12.3% across the stretch. The S&P 500 gained 0.2% over the same period, and the Nasdaq Composite was up approximately 0.5%.

Teva published its second-quarter report after the market closed on July 29, posting mixed results. While earnings for the period came in below Wall Street's target, the company delivered some news that excited investors.

Image source: Getty Images.

Teva's Q2 results at a glance With its Q2 report, Teva announced non-GAAP (adjusted) earnings of $0.02 per share -- a performance that fell far short of the average analyst estimate's call for adjusted earnings per share of $0.11 in the period. Meanwhile, sales in the period came in at $4.1 billion and surpassed the average analyst target by roughly $70 million. The generic drug leader's revenue was still down roughly 1% year over year in the period, but the decline was softer than expected -- and investors saw promise in the company's guidance and a significant new development for the stock.

Today's Change

(

-1.13

%) $

-0.40

Current Price

$

35.01

What's next for Teva? For the full-year period, Teva is guiding for adjusted earnings to be between $1.91 per share and $2.11 per share after accounting for closing and administrative costs stemming from its acquisition of Emalex. Meanwhile, the average analyst estimate had called per-share earnings of $2.16 for the year. The company also guided for sales to come in between $16.5 billion and $16.85 billion. For reference, the average Wall Street estimate had targeted sales of $16.63 billion.

With its Q2 report, Teva also announced that it was gearing up to have its stock listed directly on the New York Stock Exchange. As part of the initiative, the Israel-based company's American depositary receipts (ADRs) are set to be replaced with newly listed common stock. The new common stock is set to start trading on September 14, and the direct listing could help attract support from institutional investors and retail traders.

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Posted by Defense World Staff on Aug 1st, 2026

Avidity Partners Management LP increased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 7.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 450,100 shares of the company’s stock after acquiring an additional 32,800 shares during the quarter. Teva Pharmaceutical Industries comprises 2.7% of Avidity Partners Management LP’s investment portfolio, making the stock its 7th biggest position. Avidity Partners Management LP’s holdings in Teva Pharmaceutical Industries were worth $13,557,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. AQR Capital Management LLC grew its stake in shares of Teva Pharmaceutical Industries by 24.6% in the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after buying an additional 4,732 shares during the period. Focus Partners Wealth raised its position in shares of Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after buying an additional 1,739 shares during the period. Franklin Resources Inc. acquired a new position in Teva Pharmaceutical Industries in the second quarter valued at approximately $255,000. Flow Traders U.S. LLC acquired a new position in Teva Pharmaceutical Industries in the second quarter valued at approximately $238,000. Finally, Cerity Partners LLC grew its position in Teva Pharmaceutical Industries by 2.9% in the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock worth $768,000 after acquiring an additional 1,291 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance Shares of TEVA opened at $35.05 on Friday. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.78 and a current ratio of 0.88. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The firm has a 50-day simple moving average of $33.24 and a 200-day simple moving average of $32.73. The company has a market capitalization of $40.30 billion, a price-to-earnings ratio of 58.41, a price-to-earnings-growth ratio of 3.74 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The firm had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

More Teva Pharmaceutical Industries News Here are the key news stories impacting Teva Pharmaceutical Industries this week:

Positive Sentiment: Analyst upgrade supports the rally. Teva’s shares rose 8.2% following an analyst upgrade, indicating improved confidence in the company’s earnings outlook and branded-drug strategy. Teva Pharmaceutical Industries Stock Price Up 8.2% Following Analyst Upgrade Positive Sentiment: Higher outlook and branded-product momentum lifted sentiment. Teva raised the midpoint of its 2026 revenue guidance by $75 million, while targeting AUSTEDO revenue of $2.45 billion-$2.6 billion and AJOVY revenue of $850 million-$870 million. Management said growth across the portfolio is helping offset pressure in its established generic-drug business. Teva Lifts Sales View as Brand-Name Business Gains Traction Positive Sentiment: UZEDY delivered record sales. Strong quarterly demand for the long-acting schizophrenia treatment prompted Teva to raise its 2026 UZEDY revenue outlook. Regulatory progress for a once-monthly olanzapine injection and a Tourette syndrome candidate also reinforced the company’s pipeline narrative. Teva Lifts UZEDY Outlook After Record Sales and New FDA Progress Neutral Sentiment: Revenue exceeded expectations, but profitability did not. Second-quarter revenue was approximately $4.14 billion and benefited from innovative medicines, but earnings missed estimates. Teva reported a $576 million net loss, largely reflecting Emalex acquisition-related costs and impairment charges, making the quality and sustainability of reported earnings an investor concern. Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises Negative Sentiment: Heavy put-option activity signals hedging or bearish speculation. Investors acquired 27,659 put options, roughly 168% above typical volume. This does not prove a decline is imminent, but it suggests increased demand for downside protection after the stock’s strong recent run. Analysts Set New Price Targets A number of analysts recently issued reports on TEVA shares. Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Friday, July 17th. Truist Financial lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $42.00.

View Our Latest Stock Analysis on TEVA

Insider Buying and Selling at Teva Pharmaceutical Industries In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the transaction, the executive vice president owned 65,621 shares in the company, valued at approximately $2,237,676.10. The trade was a 61.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Richard Daniell sold 30,000 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $1,973,727. This represents a 34.98% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 300,493 shares of company stock valued at $10,537,510. 0.54% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Profile (Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

See Also Five stocks we like better than Teva Pharmaceutical Industries Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Apple’s Record Quarter Could Not Outrun Its Guidance Problem McKesson’s Compounding Keeps Adding Up Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report).

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEArgent Capital Management LLC Sells 26,822 Shares of Waste Connections, Inc. $WCN

MarketBeat Week in Review – 02/03 - 02/07Teva Pharmaceutical Industries NYSE: TEVA reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were largely offset by growth in its innovative medicines portfolio.

Chief Executive Officer Richard Francis said Teva’s growth strategy is increasingly being driven by AUSTEDO, AJOVY and UZEDY, whose combined revenue rose 43% year over year during the quarter. The company raised its full-year revenue outlook for all three products and increased the midpoint of its overall 2026 revenue guidance by $75 million.

Get TEVA alerts:

Innovative portfolio drives guidance increases Teva Pharma: Why This Generic Drug Giant Is a Smart Buy NowAUSTEDO, Teva’s treatment for tardive dyskinesia and Huntington’s disease chorea, generated $676 million in U.S. revenue during the quarter, up 33% year over year. Global revenue increased 40%, supported by a 14% increase in total prescriptions and 21% growth in milligrams dispensed, Francis said. AUSTEDO XR accounted for more than 60% of new AUSTEDO patient starts.

Teva raised AUSTEDO’s 2026 revenue guidance to a range of $2.45 billion to $2.6 billion, an increase of $50 million at the midpoint. Francis said the midpoint of the revised range reaches the company’s previously stated 2027 target of $2.5 billion and reiterated Teva’s expectation for more than $3 billion in peak sales.

2 Generic Drug Stocks Ready to Surge in 2025UZEDY, a long-acting injectable treatment for schizophrenia, posted quarterly revenue of $77 million, up 43% from a year earlier. Total prescriptions and monthly order trends increased 63%, according to Francis. Teva raised its full-year UZEDY forecast by $15 million at the midpoint to a range of $270 million to $290 million.

AJOVY, Teva’s migraine treatment, generated global revenue of $244 million, an increase of 56% year over year. U.S. revenue climbed 83%, aided by improved contracting, favorable gross-to-net trends and market-share gains, Francis said. The company lifted AJOVY’s full-year outlook by $90 million at the midpoint to $850 million to $870 million and said it sees a path to $1 billion in peak sales.

Teva is preparing for a potential fourth-quarter FDA action and U.S. launch of its long-acting injectable olanzapine product. The company said it expects no revenue contribution from the product in the fourth quarter because initial use would largely consist of samples or vouchers while payer coverage is established.

Generics pressure and biosimilar expansion Global generics revenue fell 15% year over year, primarily because of a lower contribution from generic Revlimid. Excluding generic Revlimid, Francis said the generics business was stable, with global generics down 2% and U.S. generics up 1%.

Management said lower launch activity, a softer cough-and-cold season and increased competition in some markets are expected to weigh on 2026 generics results. Teva expects global generics revenue, excluding generic Revlimid and the divestment of its Japan business, to range from flat to down low single digits in local currency for the full year.

Still, the company identified biosimilars as an emerging growth platform. Teva has 15 biosimilar products on the market and 14 in its pipeline. Francis said two of its five U.S. biosimilars are market leaders, while a third is close to taking the top position. The company expects to exceed its target of $800 million in biosimilar revenue by 2027.

Profitability, cash flow and balance sheet Teva reported a GAAP net loss of $576 million, or $0.49 per share, for the second quarter. The results included $724 million in in-process research and development expense related to Teva’s June acquisition of Emalex Biosciences, which was accounted for as an asset acquisition.

On a non-GAAP basis, Teva reported earnings per share of $0.02. Excluding the Emalex-related impact, non-GAAP EPS would have been $0.63, Chief Financial Officer Eli Kalif said. Non-GAAP gross margin increased 80 basis points to 55.4%, while non-GAAP operating margin was 9% including Emalex-related expenses. Excluding those expenses, operating margin would have been 26.6%.

Free cash flow rose 31% year over year to $622 million. Teva ended the quarter with net debt of $12.9 billion and a net-debt-to-EBITDA ratio of 2.8 times. Excluding the Emalex acquisition, the ratio would have been 2.3 times, Kalif said, putting the company on track toward its target of below 2 times by 2027.

Fitch upgraded Teva to investment grade in May, marking the company’s return to investment-grade status for the first time since 2017, according to Kalif.

Pipeline milestones ahead Teva submitted ecopipam to the FDA in June for Tourette syndrome and expects a potential launch in the first half of 2027 if approved. The company said it sees an unmet need among pediatric patients, citing an estimated 100,000 children with Tourette syndrome in the U.S., with about half receiving treatment.

The company also outlined upcoming pipeline events, including a second-half readout from its anti-IL-15 celiac disease proof-of-concept study, an expected year-end event-driven study milestone for its dual-action rescue inhaler program in asthma, and a planned fourth-quarter regulatory action for long-acting olanzapine.

Teva and partner Sanofi also added hidradenitis suppurativa and fibrostenotic Crohn’s disease as research indications for duvakitug. Eric Hughes, Teva’s head of global research and development and chief medical officer, said the company expects to pursue a traditional Phase 2b study in hidradenitis suppurativa, with primary endpoints likely assessed around 16 weeks.

Looking ahead, Teva reaffirmed its 2026 outlook for operating profit, adjusted EBITDA, EPS and free cash flow. Management said it continues to target mid-single-digit revenue growth, a 30% non-GAAP operating margin, net debt to EBITDA below 2 times and cash conversion of 80% by 2027.

About Teva Pharmaceutical Industries (NYSE:TEVA)Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?Before you consider Teva Pharmaceutical Industries, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.

While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

• Teva Pharmaceutical Indus shares are powering higher. What’s behind TEVA gains?

NYSE Listing TransitionTeva announces the replacement of its American Depositary Share (ADS) program with the direct listing of its ordinary shares on the New York Stock Exchange (NYSE).

ADSs will be exchanged on a one-for-one basis for ordinary shares, which commence trading on the NYSE on Monday, Sept. 14.

The transition aims to broaden Teva’s shareholder base, support its potential inclusion in leading indices, and optimize cost-of-capital.

Key Brands Offset Generic Drug WeaknessThe company reported adjusted earnings of two cents, missing the consensus of 25 cents.

Sales decreased 1% (-3% in local currency) to $4.142 billion, beating the Wall Street consensus of $4.047 billion. The decrease was due to lower revenues from generic products, primarily lenalidomide capsules.

The generic drug makers‘ key brands Austedo, Ajovy and Uzedy collectively grew 43% year over year in local currency to over $1 billion in revenues. Each brand grew at least 40% year over year in the quarter.

Generics global revenues were lower in the quarter mainly due to lower revenues from lenalidomide capsules (a generic version of Revlimid) in the U.S.; the biosimilars portfolio performed strongly and is on track to deliver $800 million in revenues by 2027.

The company, in its earnings conference call, said it is on track to meet its 2027 financial growth targets, with stable revenues despite challenges in the generics sector, and expects continued margin expansion driven by its innovative portfolio.

2026 Outlook and PipelineTeva expects fiscal 2026 adjusted earnings of $1.91-$2.11, including (66 cents) per share of 2026 Emalex expenses, unchanged from prior guidance.

The company marginally raised its 2026 sales guidance from $16.40 billion-$16.80 billion to $16.50 billion-$16.85 billion compared to the consensus of $16.618 billion.

Teva raised its 2026 revenue outlook for its key innovative brands, and now expects combined 2026 revenue of ~$3.7 billion, reflecting around 17% year-over-year growth at the midpoint.

The company has a robust pipeline with potential launches over the next five years, including olanzapine and ecopipam, and is increasing its biosimilars portfolio with 15 products currently in the market.

TEVA Stock Price Activity: Teva Pharmaceutical shares were up 9.25% at $34.60 at the time of publication on Wednesday, according to Benzinga Pro data.

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S.

In its upcoming report, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.08 per share, reflecting a decline of 87.9% compared to the same period last year. Revenues are forecasted to be $4.1 billion, representing a year-over-year decrease of 1.7%.

The consensus EPS estimate for the quarter has been revised 40.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

That said, let's delve into the average estimates of some Teva Pharmaceutical Industries metrics that Wall Street analysts commonly model and monitor.

The consensus among analysts is that 'Geographic Revenue- International Markets' will reach $536.52 million. The estimate indicates a year-over-year change of +8.4%.

Based on the collective assessment of analysts, 'Geographic Revenue- United States' should arrive at $1.68 billion. The estimate suggests a change of -21.9% year over year.

The average prediction of analysts places 'Geographic Revenue- United States- COPAXONE' at $59.21 million. The estimate suggests a change of -4.5% year over year.

Analysts forecast 'Geographic Revenue- United States- BENDEKA and TREANDA' to reach $30.50 million. The estimate suggests a change of -23.8% year over year.

Analysts predict that the 'Geographic Revenue- United States- AUSTEDO' will reach $594.41 million. The estimate indicates a change of +20.1% from the prior-year quarter.

The combined assessment of analysts suggests that 'Geographic Revenue- Europe- COPAXONE' will likely reach $38.75 million. The estimate indicates a change of -22.5% from the prior-year quarter.

Analysts expect 'Geographic Revenue- Europe- Respiratory products' to come in at $57.59 million. The estimate indicates a change of +4.7% from the prior-year quarter.

The consensus estimate for 'Geographic Revenue- International Markets- Generic products (including OTC and biosimilars)' stands at $425.38 million. The estimate indicates a change of +3.8% from the prior-year quarter.

Analysts' assessment points toward 'Geographic Revenue- International Markets- COPAXONE' reaching $7.25 million. The estimate indicates a year-over-year change of +3.6%.

According to the collective judgment of analysts, 'Geographic Revenue- United States- AJOVY' should come in at $80.90 million. The estimate indicates a year-over-year change of +28.4%.

The collective assessment of analysts points to an estimated 'Geographic Revenue- Europe- Generic products (including OTC and biosimilars)' of $1.10 billion. The estimate indicates a change of +5.8% from the prior-year quarter.

It is projected by analysts that the 'Geographic Revenue- Europe- AJOVY' will reach $79.05 million. The estimate indicates a change of +11.3% from the prior-year quarter.

View all Key Company Metrics for Teva Pharmaceutical Industries here>>>

Teva Pharmaceutical Industries shares have witnessed a change of -6.7% in the past month, in contrast to the Zacks S&P 500 composite's +1.7% move. With a Zacks Rank #3 (Hold), TEVA is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Companies must evolve to stay relevant in the pharmaceutical industry. Teva Pharmaceutical Industries (TEVA -1.19%) is in the midst of its own transformation, from making generic drugs and biosimilars to novel drugs that are beginning to deliver growth and profits that are catching Wall Street's eye.

Every single Wall Street analyst polled by CNN Business currently has a buy rating on the pharmaceutical stock. Based on 12-month price targets, Teva could have anywhere from 28% to 60% upside from its current price, according to the analysts.

It seems like a bold call, considering the broader stock market has left the stock in the dust. Teva is down 40% over the past decade. But sometimes, these comeback stories produce the biggest returns. Here's why Wall Street analysts are right to be bullish about the stock right now.

Image source: Getty Images.

Teva is pivoting from generics to boost growth For a while, Teva had specialized in generics and biosimilars. Generic drugs are often simple formulations that typically sell at low margins. CEO Richard Francis took over in January 2023. He has helped guide the company further into developing novel drugs. This is a riskier path because drug development is expensive and many drugs fail to reach the market. However, a successful drug enjoys years of patent protection and can generate millions, even billions, of high-margin dollars in sales.

Today's Change

(

-1.19

%) $

-0.37

Current Price

$

30.81

Revenue from generic drugs and biosimilars was $612 million in the first quarter of 2026, down 28% from a year ago on weaker generic sales. Generics and biosimilars accounted for 40% of Teva's total sales in Q1, and management expects biosimilars to continue growing and drive this group as generics become a smaller part of the business.

But branded drugs are moving the needle in the right direction. Teva's top-selling drug, Austedo, grew 41% to $559 million. Austedo is a treatment for tardive dyskinesia, a condition that causes involuntary facial movements. Management anticipates Austedo hitting $2.4 billion to $2.55 billion in sales for the full year, up from $2.26 billion in 2025.

Nearly all of Teva's other branded products are much smaller right now, but are growing at double-digit rates.

NameSales in Q1 2026Year-Over-Year Growth in Q1 2026Ajovy$87 million64%Copaxone$62 million16%Uzedy$63 million62% Source: Table created by author. Data from Teva Pharmaceutical Industries Q1 2026 earnings.

Becoming a better business for the long term Revenue growth might not jump off the page right away. Despite the impressive growth in these branded sales, Teva expects total revenue to fall from $17.3 billion in 2025 to $16.4 billion to $16.8 billion this year. The key difference here is that these are higher-quality dollars. Management is guiding for 30% operating margins in 2027 as branded sales continue to grow, up from only 12.5% last year.

Teva's biosimilars portfolio is gaining momentum, with sales expected to reach $800 million in 2027, more than offsetting lower generic sales. Additionally, Teva is bolstering its pipeline through acquisition. It recently bought Emalex Biosciences for $700 million, adding ecopipam, a developmental treatment for Tourette's syndrome in children, to its portfolio. Teva filed a New Drug Application with the U.S. Food & Drug Administration for ecopipam last month, following positive data from its Phase 3 clinical trial.

Teva's price targets are attainable At roughly $31 per share, Teva is trading at 14 times Wall Street's 2026 earnings estimates, and only 10 times 2027 estimates. The leap in earnings from this year to next is likely due to the expectation of those 30% operating margins, as reiterated by management on the company's Q1 earnings call.

That's a pretty inexpensive valuation for a company that suddenly has a lot going for it. Assuming ecopipam hits the market and branded and biosimilar sales continue to grow, Teva should be able to sustain solid earnings growth beyond next year. The low valuation leaves tons of room for that to translate to tangible investment returns.

TEVA data by YCharts. EPS = earnings per share.

If Teva delivers results that boost the market's sentiment toward the stock, even trading at just 15 times 2027 earnings estimates puts the share price above Wall Street's median price target of $40. So, these targets are certainly possible if Teva's business continues to perform well.

Determining where to allocate capital in the healthcare sector often involves choosing between established stability and aggressive growth. Both Johnson & Johnson (JNJ +1.17%) and Eli Lilly and Co (LLY +1.87%) offer unique paths for investors.

Johnson & Johnson is a diversified healthcare leader with significant operations in medical technology and pharmaceuticals. Eli Lilly has recently emerged as a growth powerhouse focused on metabolic health and weight-loss treatments. Comparing these two giants helps you decide between a stable, diversified income play and a fast-growing pharmaceutical specialist.

The case for Johnson & JohnsonJohnson & Johnson operates as a leader among healthcare stocks through its Innovative Medicine and MedTech segments. Its portfolio includes blockbusters like Darzalex, which accounted for approximately 15% of revenue in 2025. The company is currently in the middle of a strategic shift, including a planned separation of its orthopedics business.

In FY 2025, revenue reached nearly $94.2 billion, representing about 6% growth over the previous year. Net income for the period was $26.8 billion, a significant increase from the $14.1 billion reported in the prior year.

As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 0.6x. This metric compares total debt to shareholders’ equity, providing insight into how the company finances its operations. Free cash flow reached nearly $19.7 billion for the fiscal year.

The case for Eli Lilly Eli Lilly and Co has centered its growth strategy on cardiometabolic health, primarily through its treatments for diabetes and weight management. These products, including Mounjaro and Zepbound, accounted for roughly 56% of total revenue in 2025. This focus allows the company to tap into rapidly expanding global markets for obesity care and chronic disease management.

During FY 2025, revenue surged to nearly $65.2 billion, representing approximately 45% growth over the prior fiscal year. Net income followed this upward trajectory, reaching nearly $20.6 billion, reflecting strong demand and pricing power across its primary drug lines.

According to its December 2025 balance sheet, the debt-to-equity ratio is approximately 1.6x. This indicates the company uses more debt relative to its equity than its larger peer. Free cash flow reached nearly $9.0 billion for the fiscal year.

Risk profile comparisonJohnson & Johnson faces pressure under the Inflation Reduction Act to negotiate drug prices for drugs like Stelara. The company is also facing thousands of lawsuits related to its talc-containing powders, which could result in substantial settlements. Patent expirations and supply chain complexities further threaten its market share and production stability.

Eli Lilly faces heavy revenue concentration, with over half of its sales coming from just two products. The company is also navigating litigation after a court restored a breach-of-contract case brought by Teva Pharmaceuticals (TEVA +2.03%). Integration of recent acquisitions and government price negotiations remain constant financial and operational risk.

Valuation comparisonJohnson & Johnson is cheaper based on its Forward P/E and P/S ratio, while Eli Lilly commands a growth premium.

MetricJohnson & JohnsonEli Lilly andSector BenchmarkForward P/E21.9x31.8x392.9xP/S ratio6.4x14.3xSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Eli Lilly and Johnson & Johnson overlap in some healthcare segments, such as prescription drugs, while JNJ’s business is broader, also covering non-medicine healthcare products.

Eli Lilly is riding a wave of success with its GLP-1 drugs Zepbound for weight loss and Mounjaro, which is the same drug for diabetes control. There is still plenty of growth left in the treatment, and that is expected to power revenue up as high as 30% in 2026, to $85.2 billion, with close to $31 billion in net income. Its next weight-loss drug, Retatrutide, is hotly anticipated for its triple-agonist approach, which is expected to exceed the weight-loss results of Zepbound. The company is also targeting less affluent customers with a lower-cost GLP pill called Foundayo, which it sells directly to consumers.

Besides GLP-1s, Lilly is working on a small interfering RNA therapeutic targeting lipoprotein(a) for the prevention of atherosclerotic cardiovascular disease in patients with elevated lipoprotein(a) levels. Analysts believe it will be a blockbuster ($1 billion or more lifetime revenue) if approved.

Johnson & Johnson, meanwhile, is an overlooked behemoth compared to fast growers like Eli Lilly. The business has 28 products and platforms that generate more than $1 billion in annual revenue. Its pharmaceuticals arm,  Innovative Medicine, has had two FDA approvals recently, and has two more approved drug product launches this year in the E.U. and U.S. Innovative Medicine is 65% of JNJ’s annual revenue and appears to have a robust pipeline beyond those pending products. MedTech, its other arm, sells a wide range of healthcare products, including wound care, surgical instruments and implants, hip and knee replacements, and spinal implants. The recent buy of Atraverse Medical bolsters that business.

Both Lilly and JNJ are blockbuster-producing pharma giants with defensible market positions. Each is a compelling investment, but the nod here goes to Eli Lilly because its primary product, GLP-1s and related drugs, are products that most patients will take for a lifetime for weight maintenance after initial weight loss. That’s a huge, continuing market even if competition from other GLP-1s intensifies.

TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities.

“This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and development capabilities creates a clear path to getting this medicine to patients who need more treatment options.”

Under the terms of the agreement, Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar candidate. Teva will be responsible for regulatory submissions and, upon approval, commercialization of the intravenous and subcutaneous formulations in the United States, Europe, Brazil, Canada, Australia, New Zealand, Israel and Turkey.

“This agreement is aligned with Teva’s Pivot to Growth strategy and our focus on expanding our biosimilars pipeline. With our global commercial footprint and deep expertise in complex medicines, we are well positioned to help bring this biosimilar candidate to patients,” said Yolanda Tibbe, Vice President, Global Head of Biosimilars at Teva.

This strategic agreement reinforces both organizations’ commitment to broadening access to biologic medicines while promoting the long-term sustainability of healthcare systems.

About ocrelizumab

Ocrelizumab is a humanized monoclonal antibody designed to target CD20-positive B cells, which are believed to play a role in the autoimmune activity associated with multiple sclerosis. Ocrevus® (ocrelizumab) is indicated for the treatment of relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. In the U.S., the intravenous formulation is marketed as Ocrevus®, while the subcutaneous formulation is marketed separately as Ocrevus Zunovo® (ocrelizumab and hyaluronidase-ocsq). In the EU, both formulations carry the single brand name Ocrevus®.

About Multiple Sclerosis

Multiple sclerosis is a chronic, unpredictable and progressive disease of the central nervous system, which includes the brain and spinal cord. In MS, the loss of myelin, the protective sheath surrounding nerve fibers, disrupts the transmission of electrical signals to and from the brain, leading to a wide range of symptoms.

MS affects people differently. Symptoms can fluctuate, with periods of worsening (relapses) followed by partial or full recovery (remission). Over time, some patients may also experience a gradual progression of disability.

Common symptoms include fatigue, weakness, numbness or tingling, walking difficulties, spasticity, dizziness, and vision problems, among others.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

About Polpharma Biologics

Polpharma Biologics International AG is a biopharmaceutical company focused on development and manufacturing of biosimilars for supply to global markets. We manage the entire value chain: from product selection and investment allocation, through program execution to asset monetization, ensuring fast progress from idea to launch in strong collaboration with our global partners.

Our international team of senior experts has proven experience in program leadership, regulatory strategy, CMC integration, device development, clinical oversight, and quality assurance. Working with trusted CDMOs and CROs, we deliver end-to-end biosimilars, from cell line to finished product, across a range of major therapeutic areas. Our commercial partners ensure access for patients to these medicines worldwide.

Our mission is to accelerate access to biologics. To fulfill that mission, we maintain a robust, expanding pipeline of biosimilars in development. www.polpharmabiologics.com

Teva Cautionary Note Regarding Forward-Looking Statements

This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute our collaboration agreement with Polpharma Biologics for the commercialization of its biosimilar candidate to ocrelizumab, upon regulatory approval; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward-looking statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG tod

Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript

NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designationsEcopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome.

“The NDA submission for ecopipam is a significant milestone for a potential first-in-class treatment option in pediatric Tourette syndrome,” said Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer of Teva. “This reflects the momentum in our innovative pipeline through our recent acquisition of this important asset, and advances our Pivot to Growth strategy and commitment to bringing differentiated medicines for patients.”

The NDA submission is supported by positive Phase 3 data recently published in JAMA Neurology, which showed that ecopipam significantly delayed time to relapse compared with placebo in pediatric patients with Tourette syndrome who had achieved a clinical response during the open-label treatment period. In the study, ecopipam demonstrated a statistically significant benefit on the primary efficacy endpoint in pediatric patients (p = 0.008) and was generally well tolerated, with the most common adverse events related to ecopipam therapy including somnolence, insomnia, anxiety, fatigue and headache.

About Tourette Syndrome

Tourette syndrome is a chronic neuro-developmental disorder character by involuntary motor and vocal tics beginning in childhood, often between 5 and 10 years of age. For people living with Tourette syndrome, symptoms can be frequent, visible, and disruptive, affecting everyday life. Despite the current treatment options available, many patients continue to experience inadequate treatment control or treatment-limiting side effects, underscoring the need for additional options.

About ecopipam

Ecopipam is a first-in-class investigational therapy designed to block dopamine signaling at the D1 receptor. D1 receptor hypersensitivity may contribute to repetitive and compulsive behaviors associated with Tourette syndrome.

Ecopipam has received Orphan Drug and Fast Track designations from the FDA for the treatment of pediatric patients with Tourette syndrome. Orphan Drug designation is reserved for patient populations of 200,000 or fewer.

Results from the Phase 3 study in Tourette syndrome were recently published in JAMA Neurology. The primary efficacy endpoint in the study was time to relapse (based on YGTSS-TTS scale) for pediatric patients who were stable and responding to ecopipam. The study showed statistical significance between ecopipam and placebo for the primary efficacy endpoint in pediatric patients (p = 0.008). Ecopipam was generally well-tolerated in the study and the most common adverse events related to ecopipam therapy were somnolence (n = 24 [11.1%]), anxiety (n = 21 [9.7%]), headache (n = 21 [9.7%]), insomnia (n = 19 [8.8%]), tic (n = 17 [7.9%]), and fatigue (n = 14 [6.5%]). 

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Media Inquiries: [email protected] Investor Relations Inquiries: [email protected] Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause Teva’s future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.

All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “developing,” “target,” “may,” “expand,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: our ability to successfully develop, obtain regulatory approval for and commercialize ecopipam; our ability to successfully compete in the marketplace including our ability to develop and commercialize ecopipam and additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.